[go: up one dir, main page]

SG11201909168VA - Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor - Google Patents

Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor

Info

Publication number
SG11201909168VA
SG11201909168VA SG11201909168VA SG11201909168VA SG 11201909168V A SG11201909168V A SG 11201909168VA SG 11201909168V A SG11201909168V A SG 11201909168VA SG 11201909168V A SG11201909168V A SG 11201909168VA
Authority
SG
Singapore
Prior art keywords
rue
international
loos
lille
pct
Prior art date
Application number
Inventor
Robert Walczak
Carole Belanger
Vanessa Legry
Benoît Noel
Emeline Descamps
Guillaume Vidal
Mathilde Walczak
Isabelle Delbaere
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of SG11201909168VA publication Critical patent/SG11201909168VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 25 October 2018 (25.10.2018) WIP0 I PCT omits I E l° 0111111111011EIMOU 011 (10) International Publication Number WO 2018/193007 Al (51) International Patent Classification: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, A61K 31/192 (2006.01) A61K 31/444 (2006.01) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, A61K 31/194 (2006.01) A61P 1/16 (2006.01) KM, ML, MR, NE, SN, TD, TG). A61K 31/5375 (2006.01) A61P 17/02 (2006.01) A61K 45/06 (2006.01) A61P 29/00 (2006.01) Published: A61K 31/435 (2006.01) — with international search report (Art. 21(3)) (21) International Application Number: PCT/EP2018/059969 (22) International Filing Date: 18 April 2018 (18.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17305452.9 18 April 2017 (18.04.2017) EP 18305150.7 13 February 2018 (13.02.2018) EP (71) Applicant: GENFIT [FR/FR]; 885 avenue Eugene Avinee, 59120 LOOS (FR). (72) Inventors: WALCZAK, Robert; Residence Parc d'Isly, 13B rue Delezenne, 59000 LILLE (FR). BELANGER, Carole; 3 Allee du Verger, 59910 BONDUES (FR). LEGRY, Vanessa; 71 rue Bleriot, 59320 EMMERIN (FR). NOEL, Benoit; 9 rue Leonard Danel, 59120 LOOS (FR). DESCAMPS, Emeline; 9 rue Leonard Danel, 59120 LOOS (FR). VIDAL, Guillaume; 36 avenue De Lattre de Tassigny, 59350 SAINT ANDRE LEZ LILLE (FR). WALCZAK, Mathilde; Residence Parc d'Isly, 13B rue Delezenne, 59000 LILLE (FR). DELBAERE, Isabelle; 52 me Paul Lafargue, 59320 EMMERIN (FR). (74) Agent: CABINET BECKER ET ASSOCIES; 25, rue Louis le Grand, 75002 PARIS (FR). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, O TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 01 1-1 1-1 (54) Title: COMBINATION COMPRISING A PPAR AGONIST SUCH AS ELAFIBRANOR AND AN ACETYL-COA CARBOXY- el LASE (ACC) INHIBITOR C (57) : The present invention relates to a combination product and its use in therapy.
SG11201909168V 2017-04-18 2018-04-18 Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor SG11201909168VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305452 2017-04-18
EP18305150 2018-02-13
PCT/EP2018/059969 WO2018193007A1 (en) 2017-04-18 2018-04-18 Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor

Publications (1)

Publication Number Publication Date
SG11201909168VA true SG11201909168VA (en) 2019-11-28

Family

ID=61972154

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909168V SG11201909168VA (en) 2017-04-18 2018-04-18 Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor

Country Status (13)

Country Link
US (2) US11478440B2 (en)
EP (2) EP3612176A1 (en)
JP (2) JP7266530B2 (en)
KR (1) KR102699958B1 (en)
CN (2) CN110536682B (en)
AU (2) AU2018254743B2 (en)
BR (2) BR112019021914A2 (en)
CA (2) CA3057940A1 (en)
IL (1) IL269829B (en)
MX (2) MX2019012535A (en)
PH (1) PH12019502348A1 (en)
SG (1) SG11201909168VA (en)
WO (2) WO2018193006A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008542301A (en) 2005-05-26 2008-11-27 メタバシス・セラピューティクス・インコーポレイテッド Thyroid hormone-like drug for the treatment of fatty liver disease
KR20210131431A (en) 2011-10-28 2021-11-02 샤이어 휴먼 지네틱 테라피즈 인크. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
SG11201401849QA (en) 2011-10-28 2014-05-29 Lumena Pharmaceuticals Inc Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
CN107683135A (en) 2015-03-09 2018-02-09 因特克林医疗有限公司 Method for treating NASH disease and/or lipodystrophia
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
WO2018094265A2 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
CA3058806A1 (en) 2017-04-03 2018-10-11 Coherus Biosciences Inc. Ppar.gamma. agonist for treatment of progressive supranuclear palsy
CN110536682B (en) * 2017-04-18 2023-01-06 基恩菲特公司 Combinations of eprinox or a derivative thereof with anti-NASH, anti-fibrosis or anti-cholestasis agents
CN110996966A (en) 2017-06-05 2020-04-10 维京治疗公司 Composition for treating fibrosis
AU2018326785B2 (en) 2017-09-03 2023-03-02 Angion Biomedica Corp. Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors
KR20220103807A (en) 2017-10-06 2022-07-22 길리애드 사이언시즈, 인코포레이티드 Combination therapy comprising an acc inhibitor
CA3094167A1 (en) 2018-03-22 2019-09-26 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
EP3890747A4 (en) 2018-12-05 2022-08-03 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
US20220016136A1 (en) * 2018-12-05 2022-01-20 Viking Therapeutics, Inc. Compositions and methods for the treatment of liver disorders
CN111320609A (en) 2018-12-13 2020-06-23 拓臻股份有限公司 THR β receptor agonist compound and preparation method and application thereof
EP3917957A1 (en) * 2019-01-28 2021-12-08 Maple Biotech LLC Psmp antagonists for use in treatment of fibrotic disease of the lung, kidney or liver
US20220133738A1 (en) 2019-02-12 2022-05-05 Mirum Pharmaceuticals, Inc. Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
US20220288053A1 (en) * 2019-04-04 2022-09-15 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
EP3952868A1 (en) * 2019-04-09 2022-02-16 Genfit Combination of nitazoxanide and elafibranor for the treatment of immune diseases or inflammation
BR112021020234A2 (en) * 2019-04-10 2021-12-07 Genfit Combination therapy comprising compounds of formula (i) and glp-1 receptor agonists
WO2020227549A1 (en) 2019-05-08 2020-11-12 Aligos Therapeutics, Inc. MODULATORS OF THR-β AND METHODS OF USE THEREOF
EP3996698A1 (en) * 2019-07-09 2022-05-18 DSM IP Assets B.V. Reducing the viral activity of elafibranor with riboflavin or dha
CN116942684A (en) * 2020-02-20 2023-10-27 甘莱制药有限公司 Pharmaceutical composition for treating steatohepatitis and preparation method thereof
EP4137134A4 (en) 2020-04-13 2024-08-07 Aptabio Therapeutics Inc. MEDICATION AGAINST PULMONARY FIBROSIS WITH PYRAZOLE DERIVATIVE
KR102386097B1 (en) 2020-04-13 2022-04-14 압타바이오 주식회사 composition of pyrazole derivatives for treatment of pulmonary fibrosis
JP2023522339A (en) * 2020-04-14 2023-05-30 アメリミューン リミテッド ライアビリティ カンパニー Treatment of diseases caused by RNA viruses
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
BR112022023128A2 (en) * 2020-05-22 2022-12-20 Durect Corp NON-ALCOHOLIC STEATETOHEPATITIS (NASH) TREATMENT
CN115916181A (en) * 2020-05-22 2023-04-04 度勒科特公司 Treatment of non-alcoholic steatohepatitis (NASH)
KR20220017851A (en) * 2020-08-05 2022-02-14 주식회사 엘지화학 Use of caspase inhibitor in alleviation or treatment of osteoarthritis
JP2023539639A (en) 2020-08-25 2023-09-15 イーライ リリー アンド カンパニー SSAO inhibitor polymorphism
WO2022051323A1 (en) * 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a ppar agonist
CN112402431A (en) * 2020-12-20 2021-02-26 台州学院 New use of paricalcitol in the preparation of medicaments for the treatment of cholestatic liver injury
EP4267124A1 (en) * 2020-12-22 2023-11-01 Northsea Therapeutics B.V. Combination therapies comprising oxygen-containing structurally enhanced fatty acids for treatment of non-alcoholic steatohepatitis
WO2022238450A1 (en) * 2021-05-11 2022-11-17 Genfit Ppar-agonists for use in the treatment of liver failure
CN116008558B (en) * 2022-11-01 2024-04-02 吉林大学 Application of extracellular matrix elastin degradation product in preparation of products for diagnosing or delaying neurodegenerative diseases
WO2025039000A1 (en) * 2023-08-17 2025-02-20 New York Society for the Relief of the Ruptured and Crippled, maintaining the Hospital for Special Prevention and treatment of fibrosis through inhibition or upregulation of specific proteins

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2841900B1 (en) 2002-07-08 2007-03-02 Genfit S A NOVEL SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES
CA2550576A1 (en) * 2004-01-08 2005-08-11 Genfit 1,3-diphenylprop-2-en-1-one derivative compounds, preparation method thereof and uses of same
ES2441665T3 (en) 2009-11-26 2014-02-05 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives to treat liver disorders
WO2011080276A1 (en) * 2009-12-29 2011-07-07 Genfit Pharmaceutical combinations comprising a dpp-4 inhibitor and a 1,3-diphenylprop-2-en-1-one derivative
ES2602111T3 (en) 2010-09-30 2017-02-17 Pfizer Inc N1-pyrazoloespirocetone acetyl-CoA carboxylase inhibitors
DK2948137T3 (en) * 2013-01-18 2019-01-07 Genfit METHODS OF TREATING FIBROSE AND CANCER TYPES
SG10201913286PA (en) * 2013-01-18 2020-02-27 Cardioxyl Pharmaceuticals Inc Pharmaceutical compositions comprising nitroxyl donors
WO2015192854A2 (en) * 2014-06-16 2015-12-23 Aarhus Universitet Methods and tools for predicting steatohepatitis
SG11201701871SA (en) 2014-09-12 2017-04-27 Tobira Therapeutics Inc Cenicriviroc combination therapy for the treatment of fibrosis
FR3027228B1 (en) * 2014-10-20 2016-12-09 Valbiotis COMPOSITION COMPRISING A MIXTURE OF PLANT EXTRACTS AND USE FOR ACTING ON GLUCIDIC AND / OR LIPID METABOLISM
HK1243369A1 (en) 2015-01-09 2018-07-13 吉利德阿波罗公司 Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
WO2016153948A1 (en) * 2015-03-20 2016-09-29 Deuterx, Llc Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2, 4-diones for treatment of medical disorders
AU2016235263A1 (en) * 2015-03-26 2017-10-12 T3D Therapeutics, Inc. Methods of treating liver disease using indane acetic acid derivatives
CA3152584C (en) * 2016-11-10 2024-02-13 Galmed Research And Development Ltd. Treatment for fibrosis
CN110536682B (en) * 2017-04-18 2023-01-06 基恩菲特公司 Combinations of eprinox or a derivative thereof with anti-NASH, anti-fibrosis or anti-cholestasis agents

Also Published As

Publication number Publication date
MX2019012535A (en) 2020-08-17
BR112019021914A2 (en) 2020-05-26
MX2019012534A (en) 2020-08-17
IL269829A (en) 2019-11-28
BR112019021910A2 (en) 2020-05-26
AU2018253885B2 (en) 2024-04-11
JP7266531B2 (en) 2023-04-28
KR20190136079A (en) 2019-12-09
WO2018193007A1 (en) 2018-10-25
CN110536682A (en) 2019-12-03
CN110536682B (en) 2023-01-06
IL269829B (en) 2022-05-01
AU2018254743A1 (en) 2019-10-31
MX393936B (en) 2025-03-24
CA3057940A1 (en) 2018-10-25
WO2018193006A1 (en) 2018-10-25
AU2018253885A1 (en) 2019-11-14
US11478440B2 (en) 2022-10-25
EP3612176A1 (en) 2020-02-26
US11484517B2 (en) 2022-11-01
JP2020517612A (en) 2020-06-18
PH12019502348A1 (en) 2020-12-07
JP7266530B2 (en) 2023-04-28
CN110536683A (en) 2019-12-03
KR102699958B1 (en) 2024-08-29
US20200121625A1 (en) 2020-04-23
US20200206169A1 (en) 2020-07-02
CA3058542A1 (en) 2018-10-25
EP3612175A1 (en) 2020-02-26
JP2020517621A (en) 2020-06-18
AU2018254743B2 (en) 2024-04-11

Similar Documents

Publication Publication Date Title
SG11201909168VA (en) Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
SG11201906041QA (en) Pharmaceutical compositions for combination therapy
SG11201907673YA (en) Pharmaceutical compositions for combination therapy
SG11201906987RA (en) Combination of a ppar agonist with a fxr agonist
SG11201906891RA (en) Methods for the administration of certain vmat2 inhibitors
SG11201901390TA (en) Tetracycline compounds and methods of treatment
SG11201907034PA (en) Methods of treating influenza
SG11201902938TA (en) Compounds, devices, and uses thereof
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201806845VA (en) Moisturizing compositions and uses thereof
SG11201907776WA (en) Replication lag-constrained deletion of data in a large-scale distributed data storage system
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201907896PA (en) Optical system for monitoring the movement of people through a passageway
SG11201807549TA (en) Combination of a cxcr4 antagonist and an immune checkpoint inhibitor
SG11201906313SA (en) A polypeptide linker for preparing multispecific antibodies
SG11201901228QA (en) Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
SG11201809356YA (en) Multilayer coating and process of preparing the multilayer coating
SG11201901438VA (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
SG11201900883UA (en) Combination treatment for hematological cancers
SG11201810934TA (en) Microparticles comprising a sulphur-containing compound
SG11201907199QA (en) Cancer treatment
SG11201900515PA (en) Succinate forms and compositions of bruton's tyrosine kinase inhibitors